OliX Pharmaceuticals, a South Korea-based biotechnology company focused on RNA interference (RNAi) therapeutics, announced that it has secured approximately KRW 110 billion (about $81 million) through a third-party allotment of newly issued common shares. The investment was made jointly by BOLD, the corporate venture capital fund of L’Oréal, and Weiss Asset Management LP.
The financing brings together a strategic corporate partner and a major global investor, highlighting confidence in OliX’s proprietary small interfering RNA (siRNA) platform and long-term growth prospects.
BOLD serves as L’Oréal’s venture investment arm, backing beauty, biotechnology, and technology companies with disruptive innovation potential. Weiss Asset Management, which previously invested in OliX in August 2025, participated in the latest financing round as part of its continued support for the company.
OliX plans to use the newly raised capital to advance its siRNA-based development programs across multiple therapeutic areas, including projects focused on skin and hair conditions. The company also expects the investment to deepen its strategic partnership with L’Oréal, strengthen its research capabilities, and accelerate product development efforts.
The company’s technology platform, known as OASIS (OliX Advanced Small Interfering RNA System), is designed to enhance gene-silencing efficiency while enabling tissue-specific delivery. Using this platform, OliX is advancing RNAi therapeutics for indications including hair loss, age-related macular degeneration, hypertrophic scars, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and cardiometabolic disorders.
Under its long-term “OliX 2.0 Roadmap,” the company is also developing next-generation delivery technologies targeting the central nervous system and adipose tissue while expanding its pipeline of RNAi-based therapies.
KEY QUOTES:
“We are excited to strengthen our scientific partnership with OliX with an equity investment by BOLD. This strategic collaboration combines OliX’s world-class siRNA platform capabilities with L’Oréal’s century-long commitment to beauty innovation and expertise across biology, tech, and formulation. We are convinced that together we’ll accelerate in creating the future of beauty for the benefit of consumers globally with new levels of performance backed by advanced biology and robust scientific proof.”
Guive Balooch, Global Managing Director of Open Innovation and Augmented Beauty, L’Oréal
“We are delighted to secure funding from BOLD and Weiss. Their support reflects strong confidence in our partnership and shared vision for innovation. The joint participation of a global strategic partner and a major investor reflects strong market confidence in the company’s technological competitiveness and future growth potential.”
Dong Ki Lee, CEO, OliX Pharmaceuticals
